Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group has had its marketing authorisation application for a fixed-dose Prusogliptin and Metformin extended-release tablet accepted by China’s National Medical Products Administration, marking a significant step in expanding its diabetes treatment portfolio. The combination therapy, built around CSPC’s Class 1 innovative DPP-4 inhibitor prusogliptin and the widely used biguanide metformin, targets adult patients with type 2 diabetes who are inadequately controlled on metformin alone or already on dual therapy, and clinical data show improved and sustained glucose-lowering effects, a lower incidence of hypoglycemia, and a favourable safety profile compared with metformin monotherapy. The once-combination, extended-release formulation is designed to simplify regimens, improve adherence and accommodate patients with mild to moderate renal impairment without dose adjustment, while the company simultaneously advances a triple-therapy candidate combining prusogliptin, dapagliflozin and metformin, reinforcing its positioning in China’s competitive diabetes care market and signalling potential long-term benefits for patients and prescribers if approvals are secured.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company focused on the research, development and commercialization of innovative drugs and formulations, particularly in chronic disease areas such as diabetes. The group develops both novel Class 1 drugs and advanced combination therapies aimed at improving treatment efficacy, safety and patient adherence in the Chinese and broader Asian healthcare markets.
YTD Price Performance: 8.90%
Average Trading Volume: 127,672,380
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$105.6B
See more data about 1093 stock on TipRanks’ Stock Analysis page.